ECSP20082338A - Receptores del factor de crecimiento quimérico - Google Patents

Receptores del factor de crecimiento quimérico

Info

Publication number
ECSP20082338A
ECSP20082338A ECSENADI202082338A ECDI202082338A ECSP20082338A EC SP20082338 A ECSP20082338 A EC SP20082338A EC SENADI202082338 A ECSENADI202082338 A EC SENADI202082338A EC DI202082338 A ECDI202082338 A EC DI202082338A EC SP20082338 A ECSP20082338 A EC SP20082338A
Authority
EC
Ecuador
Prior art keywords
cells
growth factor
effort
chimerical
receptors
Prior art date
Application number
ECSENADI202082338A
Other languages
English (en)
Spanish (es)
Inventor
Nicola Kaye Price
John Stephen Bridgeman
Original Assignee
Instil Bio Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63042840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP20082338(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Instil Bio Uk Ltd filed Critical Instil Bio Uk Ltd
Publication of ECSP20082338A publication Critical patent/ECSP20082338A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/196—Thrombopoietin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/35—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
ECSENADI202082338A 2018-06-21 2020-12-18 Receptores del factor de crecimiento quimérico ECSP20082338A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1810181.6A GB201810181D0 (en) 2018-06-21 2018-06-21 Cells expressing chimeric recominant growth factor receptors

Publications (1)

Publication Number Publication Date
ECSP20082338A true ECSP20082338A (es) 2021-02-26

Family

ID=63042840

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202082338A ECSP20082338A (es) 2018-06-21 2020-12-18 Receptores del factor de crecimiento quimérico

Country Status (19)

Country Link
US (1) US20210205365A1 (https=)
EP (1) EP3810646A1 (https=)
JP (2) JP2021527425A (https=)
KR (1) KR20210022690A (https=)
CN (1) CN112601759A (https=)
AU (1) AU2019289202B2 (https=)
BR (1) BR112020026233A2 (https=)
CA (1) CA3104079A1 (https=)
CL (1) CL2020003319A1 (https=)
CO (1) CO2020016052A2 (https=)
CR (1) CR20200624A (https=)
EA (1) EA202190100A1 (https=)
EC (1) ECSP20082338A (https=)
GB (1) GB201810181D0 (https=)
IL (1) IL279469A (https=)
MX (1) MX2020014257A (https=)
PH (1) PH12020500678A1 (https=)
SG (1) SG11202012726QA (https=)
WO (1) WO2019243835A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
GB201900858D0 (en) * 2019-01-22 2019-03-13 Price Nicola Kaye Receptors providing targeted costimulation for adoptive cell therapy
BR112022011795A2 (pt) 2019-12-20 2022-08-30 Instil Bio Uk Ltd Métodos para preparar e isolar uma população terapêutica de linfócitos e para tratar câncer em um indivíduo, população terapêutica de linfócitos, bolsa criopreservada, recipiente flexível, e, sistema para extração de linfócitos
EP4110355A1 (en) * 2020-02-24 2023-01-04 The United States of America, as represented by the Secretary, Department of Health and Human Services Nk cells or t cells expressing hematopoietic growth factor receptors and use for treating cancer
EP4263807A2 (en) 2020-12-18 2023-10-25 Instil Bio (Uk) Limited Processing of tumor infiltrating lymphocytes
EP4262828A1 (en) 2020-12-18 2023-10-25 Instil Bio (Uk) Limited Tumor infiltrating lymphocytes and anti-cd47 therapeutics
JP2023554425A (ja) 2020-12-18 2023-12-27 インスティル バイオ （ユーケイ） リミテッド 腫瘍浸潤リンパ球の処理
US20250288666A1 (en) 2021-07-14 2025-09-18 Synthekine, Inc. Methods and compositions for use in cell therapy of neoplastic disease
WO2025076134A1 (en) * 2023-10-03 2025-04-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nk cells or t cells expressing chimeric hematopoietic growth factor receptors and methods of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69941126D1 (de) * 1998-09-23 2009-08-27 Zymogenetics Inc Cytokinerezeptor zalpha11
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
US20030096339A1 (en) * 2000-06-26 2003-05-22 Sprecher Cindy A. Cytokine receptor zcytor17
US20140047572A1 (en) * 2012-08-13 2014-02-13 University Of Rochester Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury
EP4166148B1 (en) * 2014-06-06 2026-02-18 Memorial Sloan-Kettering Cancer Center Mesothelin-targeted chimeric antigen receptors and uses thereof
GB201522097D0 (en) * 2015-12-15 2016-01-27 Cellular Therapeutics Ltd Cells
WO2018175476A1 (en) * 2017-03-20 2018-09-27 Baylor College Of Medicine Transgenic c-mpl provides ligand-dependent co-stimulation and cytokine signals to tcr-engineered cells

Also Published As

Publication number Publication date
AU2019289202A1 (en) 2021-01-14
JP2024156656A (ja) 2024-11-06
CR20200624A (es) 2021-06-24
CL2020003319A1 (es) 2021-07-09
CA3104079A1 (en) 2019-12-26
US20210205365A1 (en) 2021-07-08
AU2019289202B2 (en) 2024-10-31
MX2020014257A (es) 2021-07-21
JP2021527425A (ja) 2021-10-14
SG11202012726QA (en) 2021-01-28
CO2020016052A2 (es) 2021-01-29
EA202190100A1 (ru) 2021-04-23
EP3810646A1 (en) 2021-04-28
WO2019243835A1 (en) 2019-12-26
KR20210022690A (ko) 2021-03-03
IL279469A (en) 2021-01-31
BR112020026233A2 (pt) 2021-04-20
PH12020500678A1 (en) 2021-07-12
CN112601759A (zh) 2021-04-02
GB201810181D0 (en) 2018-08-08

Similar Documents

Publication Publication Date Title
ECSP20082338A (es) Receptores del factor de crecimiento quimérico
Hickson et al. Challenges and opportunities for stem cell therapy in patients with chronic kidney disease
MX2020003945A (es) Tratamiento de enfermedades oculares y cancer de colon metastasico con vegf-trap humano modificado post-traduccionalmente .
Grote et al. Toll-like receptor 2/6-dependent stimulation of mesenchymal stem cells promotes angiogenesis by paracrine factors
CO2020006865A2 (es) Composiciones y métodos para el agotamiento de células cd5+
AR057582A1 (es) Agentes para suprimir la induccion de linfocitos t citotoxicos
RU2017111300A (ru) Центральные т-клетки памяти для адоптивной т-клеточной терапии
MX2020005849A (es) Células madre y progenitoras hematopoyéticas humanas cd34+ modificadas con crispr-cas9 y sus usos.
MX2016013158A (es) Productos de celulas t modificadas de genes de composicion definida.
Han et al. Immunosuppressive mechanisms of embryonic stem cells and mesenchymal stem cells in alloimmune response
ES2910115T3 (es) Células madre mesenquimales preacondicionadas con trombina para el tratamiento de la EIH neonatal
CL2017002357A1 (es) Método de obtención de una composición que contiene una población específica de células mesenquimales de cordón umbilical y sus usos
MX2022003039A (es) Metodo de seleccion de donantes universales para identificar donantes de celulas nk.
MX2020004806A (es) Composiciones y métodos para el agotamiento de células cd2+.
CO2020007275A2 (es) Pautas posológicas para la movilización de células madre y progenitoras hematopoyéticas
Bader et al. Regulatory T cell approaches for graft-versus-host disease prevention
US20170021002A1 (en) Augmentation of cancer and cancer endothelial vaccine immunogenicity by histone deacetylase inhibitors
WO2020037120A4 (en) Il7-il15 txm compositions and methods
KR20160144780A (ko) 편도 유래 중간엽 줄기세포로부터 건 세포의 분화방법
AR131998A1 (es) Terapia celular para el tratamiento de enfermedades autoinmunes sistémicas
Silvestre et al. Engineered CD19-CAR NK cells as an off-the-shelf alternative to B cell leukemia and lymphoma treatment
PL438908A1 (pl) Sposób hodowli immortalizowanych linii ludzkich mezenchymalnych komórek macierzystych (MSC), kompozycja czynników aktywnych zawartych w nadsączu otrzymanych tym sposobem i zastosowanie
Manzar et al. Human iPS Cell-Derived Insulin Producing Cells Form OrganoidsIn VivoThat Are Glucose Responsive in Diabetic Mice.: Abstract# 2947
Dai et al. Suppression of Allograft Rejection By a Novel Protein ESAT-6.: Abstract# D2759
Klamer et al. Strategies to Improve Immune Reconstitution After Haematopoietic Stem Cell Transplantation